SCHEMBL4819346

SCHEMBL4819346

CC1CCN(c2c(-c3cc(F)ccc3Cl)c(C#N)nc3ncnn23)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN2 Q96KS0 4/20 0.42
ALDH1A1 P00352 4/20 0.41
LMNA P02545 4/20 0.41
KDM4E B2RXH2 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
NPC1 O15118 1/20 0.41
STAT6 P42226 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
RCE1 Q9Y256 1/20 0.40
PDE2A O00408 6/20 0.39
MAPT P10636 3/20 0.38
TSHR P16473 3/20 0.37
HPGD P15428 1/20 0.37
ALOX15 P16050 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HSD17B10 Q99714 1/20 0.37
GLA P06280 1/20 0.36
GRM5 P41594 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3423833 0.93 EGLN2 (0.42) EGLN2ALDH1A1LMNAKDM4ENPSR1
SCHEMBL5462930 0.82 EGLN2 (0.44) EGLN2ALDH1A1LMNAKDM4ENPSR1
SCHEMBL5746793 0.82 EGLN2 (0.43) EGLN2ALDH1A1LMNAKDM4ENPSR1
SCHEMBL5593422 0.81 EGLN2 (0.41) EGLN2ALDH1A1LMNAKDM4ENPSR1
SCHEMBL6067962 0.79 EGLN2 (0.48) EGLN2ALDH1A1LMNAKDM4ENPSR1
SCHEMBL3424653 0.79 PDE2A (0.45) EGLN2ALDH1A1LMNANPSR1PDE2A
SCHEMBL5593357 0.79 KDM1A (0.41) EGLN2ALDH1A1LMNAKDM4ENPSR1
SCHEMBL3424814 0.79 PDE2A (0.46) ALDH1A1LMNANPSR1HTTPDE2A
SCHEMBL5593085 0.77 EGLN2 (0.46) EGLN2ALDH1A1LMNAKDM4ENPSR1
SCHEMBL3429527 0.76 PDE2A (0.42) EGLN2ALDH1A1LMNAKDM4ENPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020068744-A1 Substituted-triazolopyrimidines as anticancer agents AMERICAN HOME PRODUCTS CORPORATION 2002-06-06 US claimed
US-7329663-B2 Substituted-triazolopyrimidines as anticancer agents WYETH (US) 2008-02-12 US disclosed
US-20020068744-A1 Substituted-triazolopyrimidines as anticancer agents AMERICAN HOME PRODUCTS CORPORATION 2002-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068744-A1 Substituted-triazolopyrimidines as anticancer agents TUBB3, TUBA1C, TUBB1 EGLN2 3423/4885ALDH1A1 2231/4885LMNA 2723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.